LOGIN

International Epidemiology Databases to Evaluate AIDS

Home >> Publications >> Impact of Viral Load Use on Treatment Switch in Perinatally HIV-Infected Children in Asia

Publication

Author(s):

Mohamed TJ1, Teeraananchai S2, Kerr S2, Phongsamart W3, Nik Yusoff NK4, Hansudewechakul R5, Ly PS6, Nguyen LV7, Sudjaritruk T8, Lumbiganon P9, Do VC10, Kurniati N11, Kumarasamy N12, Wati DK13, Fong MS14, Nallusamy R15, Kariminia A16, Sohn AH17

Pub Title:

Impact of Viral Load Use on Treatment Switch in Perinatally HIV-Infected Children in Asia

Pub Date:

Oct 31 2016

Pub Region(s):

Asia-Pacific

Journal:

Title: 
AIDS Res Hum Retroviruses.

PubMed: 27758114
Pub PDF:

BACKGROUND: We sought to assess the impact of routine HIV viral load (VL) monitoring on the incidence of switching from a first- to a second-line antiretroviral therapy (ART) regimen, and to describe factors associated with switch.

METHODS: Data from a regional cohort of 16 clinical programs in six Asian countries were analyzed. Second-line switch was defined as a change from a non-nucleoside reverse transcriptase inhibitor (NNRTI) to a protease inhibitor (PI) or vice versa, and ≥1 of the following: (1) reported treatment failure by local criteria, (2) switch of ≥1 additional drug, or (3) a preceding HIV VL ≥1,000 copies/ml. Routine VL was having ≥1 test after ≥24 weeks of ART and ≥1 time/year thereafter. Factors associated with time to switch were evaluated with death and loss to follow-up as competing risks.

RESULTS: A total of 2,398 children were included in this analysis. At ART initiation, the median (interquartile range) age was 6.0 (3.3-8.9) years, more than half had WHO stage 3 or 4, the median CD4 was 189 (47-456) cells/mm3, 93% were on NNRTI-based first-line ART, and 34% had routine VL monitoring. Treatment switch occurred in 17.6% of patients, at a median of 35 (22-49) months. After adjusting for country, sex, first ART regimen, and CD4% at ART initiation, children with routine VL monitoring were 1.46 (95% confidence interval 1.11-1.93) times more likely to be switched (p = .007).

CONCLUSION: Scale-up of VL testing will lead to earlier identification of treatment failure, and it can help guide earlier switches to prevent resistance.

The following websites provide guidelines and policies when citing from PubMed®: http://www.ncbi.nlm.nih.gov/books/NBK7243/
http://www.nlm.nih.gov/bsd/policy/cit_format.html

Citation:

AIDS Res Hum Retroviruses. 2016 Oct 31. [Epub ahead of print] Impact of Viral Load Use on Treatment Switch in Perinatally HIV-Infected Children in Asia. Mohamed TJ1, Teeraananchai S2, Kerr S2, Phongsamart W3, Nik Yusoff NK4, Hansudewechakul R5, Ly PS6, Nguyen LV7, Sudjaritruk T8, Lumbiganon P9, Do VC10, Kurniati N11, Kumarasamy N12, Wati DK13, Fong MS14, Nallusamy R15, Kariminia A16, Sohn AH17